Home » Drug Information » FDA Approved Drugs » 2001
Medical Areas: Dermatology | Nephrology | Obstetrics/Gynecology (Women’s Health) | Pulmonary/Respiratory Diseases | Family Medicine | Infections and Infectious Diseases | Vaccines
View By:YearCompanyConditionsTherapeutic AreasDrug Names
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Approval Status: Approved November 2001
Treatment Area: Bacterial infections
Invanz is a once-daily injectable antibiotic approved for use in
adults for the treatment of moderate to severe infections caused by
common gram-positive and gram-negative aerobic and anaerobic
bacteria. Included, are community-acquired pneumonia,
intra-abdominal, skin, urinary tract, kidney and post-surgical
Prior to administration, Invanz must be reconstituted and
The approval of Invanz is supported by studies conducted in more
than 1,900 subjects, in five infectious disease categories.
Treatment ranged from three to 14 days. Invanz exhibited an
excellent safety profile and showed success rates equivalent to
those of comparator antibiotics.
Adverse events associated with the use of Invanz may include
(but are not limited to) the following:
- Infused vein complications
- Vaginitis in females
Mechanism of Action
Invanz (ertapenem sodium) is a structurally unique 1-(beta)
methyl-carbapenem related to a class of antibiotics known as
beta-lactams, which includes penicillins and cephalosporins. Invanz
works by blocking the formation of bacterial cell walls, thereby
causing cell death.
For additional information on Invanz, please visit